Profile
Denis G.
Bosc worked as a Senior Director, Operations Director, and Director of Manufacturing & Operations in various biotech companies from 2007 to 2012 and from 2008 to 2010.
He also worked as a Vice President of Chemistry, Manufacturing & Control in NervGen Pharma Corp.
in 2019-2020.
Bosc holds a doctorate degree from the University of Manitoba.
Former positions of Denis G. Bosc
Companies | Position | End |
---|---|---|
NERVGEN PHARMA CORP. | Corporate Officer/Principal | 2020-03-31 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 2012-09-30 |
SQI DIAGNOSTICS INC. | Corporate Officer/Principal | 2010-07-31 |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 2008-07-31 |
Training of Denis G. Bosc
University of Manitoba | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SQI DIAGNOSTICS INC. | Health Technology |
NERVGEN PHARMA CORP. | Health Technology |
Private companies | 2 |
---|---|
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Denis G. Bosc